GlassScriptPhysician profile
Meegan C Chestnut
NPI 1255513636
$3,590.23
in general payments reported to CMS, 2019-2025
34 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $230 · 2021: $293 · 2022: $96.99 · 2023: $488 · 2024: $789 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $508.92 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $467.09 | 2019-2025 | Airsupra, Xigduo, Breztri |
| Pfizer INC. | $436.98 | 2019-2024 | |
| Amgen INC. | $205.75 | 2019-2024 | Krystexxa |
| Merck Sharp & Dohme LLC | $157.13 | 2019-2021 | |
| Abbott Laboratories | $113.80 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $113.33 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $99.18 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $64.15 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $56.68 | 2019-2021 | |
| Astellas Pharma US INC | $56.04 | 2019-2024 | Veozah |
| Sanofi Pasteur INC. | $51.46 | 2019-2020 | |
| Allergan, INC. | $35.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.76 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.31 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $30.44 | 2024-2025 | Contrave |
| Biohaven Pharmaceuticals, INC. | $30.12 | 2021 | |
| Hologic Sales and Service, LLC | $28.83 | 2025 | Aptima |
| Vanda Pharmaceuticals INC. | $28.39 | 2022 | |
| Amarin Pharma, INC. | $27.06 | 2019 | |
| Redhill Biopharma INC. | $24.11 | 2020 | |
| Flowonix Medical Incorporated | $23.76 | 2019 | |
| Esperion Therapeutics, INC. | $22.48 | 2025 | Nexletol |
| Medtronic, INC. | $20.86 | 2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $20.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.69 | 2024 | |
| Viiv Healthcare Company | $17.64 | 2024 | Apretude |
| Daiichi Sankyo INC. | $14.91 | 2020 | |
| Dexcom, INC. | $14.84 | 2019 | |
| Medtronic USA, INC. | $11.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meegan Chestnut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.